Plain-English translation of NCT06488625 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new form of nicotinamide—a B vitamin—called CICR-NAM (controlled-ileocolonic-release nicotinamide) to see if it can help treat ulcerative colitis. The study will compare this medication at two different doses against a placebo (inactive pill) over one year. Researchers want to know if this treatment can reduce inflammation and help people feel better.
Ulcerative colitis causes painful inflammation in the colon and can significantly impact quality of life. Current treatments don't work for everyone or may cause side effects, so doctors and researchers are looking for new options to help patients manage their disease more effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will take 6 tablets by mouth every day for one year—some people will get the active medication at a lower or higher dose, and others will receive placebo tablets that look identical. The study lasts 52 weeks total: the first 12 weeks focus on improving your symptoms (induction phase), and the remaining 40 weeks focus on keeping you well (maintenance phase). You will have regular visits with the study team for check-ups, blood tests, and possibly colonoscopies to monitor how well the treatment is working and ensure your safety.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Germany